Lumos Pharma Virtual KOL Event: Review of Phase 2 OraGrowtH Trials and New Analyses of Oral LUM-201 for Pediatric Growth Hormone Deficiency
About The Event
Join Lumos Pharma for a virtual KOL event featuring Andrew Dauber, M.D., M.M.Sc.,(Children’s National Hospital), Fernando Cassorla, M.D. (Institute of Maternal and Child Research at the University of Chile), and Leslie Soyka, M.D., M.M.Sc., (UMass Memorial Health, UMass Chan Medical School), who will discuss the current treatment landscape for patients with pediatric growth hormone deficiency (PGHD) and the therapeutic potential for LUM-201, an oral investigational drug being developed by Lumos Pharma. The event will focus on reviewing the topline results and additional data from OraGrowtH clinical trials evaluating LUM-201 as a treatment for PGHD:
- OraGrowtH210 — a multi-national Phase 2 study of LUM-201 in naïve to treatment, prepubertal patients with PGHD, investigating a predictive enrichment marker (PEM) strategy to select subjects likely to respond to therapy.
- OraGrowtH212 — a single-site Phase 2 pharmacokinetics and pharmacodynamics study of LUM-20 in patients with PGHD, investigating the effects of LUM-201 administration on growth hormone release over time.
Rick Hawkins, the CEO and Chairman of Lumos Pharma, will review summary highlights from both trials. LUM-201 has received Orphan Drug Designation in both the US and EU.
A live question and answer will follow the formal presentations.